Why Two-Thirds of Employees Quit Their GLP-1 Before It Works

Here is the statistic almost nobody discusses during the GLP-1 coverage debate: nearly two-thirds of patients stop taking GLP-1 medications before they reach the minimum threshold for meaningful clinical results. For employer health plans, that number should change the conversation. Millions of dollars are being spent on medications that many members discontinue before the treatment can fully work, while the underlying metabolic conditions continue progressing underneath.

When an employee begins GLP-1 therapy, the employer health plan immediately begins paying. The expectation is that those costs will eventually be offset by improved health outcomes. But what happens when the employee stops treatment before reaching meaningful clinical improvement? The plan absorbs the cost, the health improvements never fully materialize, and the organization is left funding an incomplete intervention.

Why Employees Stop

Employees discontinue GLP-1 therapy for many reasons. Some experience side effects. Others become frustrated with slow progress. Some lose insurance coverage or face affordability challenges. Others simply lack the ongoing support necessary to stay engaged long enough to see meaningful results. What becomes clear is that medication access alone is rarely enough. Sustainable health improvement typically requires physician oversight, ongoing coaching, accountability, lifestyle integration, clinical monitoring, and long-term engagement.

The Real Opportunity

The future of metabolic health management is not simply about expanding access to medications. It is about creating systems that help people achieve lasting results. The employers that will be most successful over the next decade will not necessarily be those spending the most on GLP-1 medications. They will be the organizations that combine clinical care, accountability, measurement, and long-term engagement into a comprehensive metabolic health strategy. Because a drug is a tool. A program is an outcome. And outcomes are what ultimately matter.